Cargando…
Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer
Biomarkers of response are needed in breast cancer to stratify patients to appropriate therapies and avoid unnecessary toxicity. We used peripheral blood gene expression and cell-type abundance to identify biomarkers of response and recurrence in neoadjuvant chemotherapy–treated patients with breast...
Autores principales: | Axelrod, Margaret L., Wang, Yu, Xu, Yaomin, Sun, Xiaopeng, Bejan, Cosmin A., Gonzalez-Ericsson, Paula I., Nunnery, Sara, Bergman, Riley E., Donaldson, Joshua, Guerrero-Zotano, Angel L., Massa, Chiara, Seliger, Barbara, Sanders, Melinda, Mayer, Ingrid A., Balko, Justin M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604512/ https://www.ncbi.nlm.nih.gov/pubmed/36304942 http://dx.doi.org/10.1158/2767-9764.CRC-22-0023 |
Ejemplares similares
-
Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance
por: James, Jamaal L, et al.
Publicado: (2023) -
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
por: Gonzalez-Ericsson, Paula I., et al.
Publicado: (2021) -
MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression
por: Franklin, Derek A., et al.
Publicado: (2020) -
Management of toxicity to isoform α-specific PI3K inhibitors
por: Nunnery, S E, et al.
Publicado: (2019) -
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
por: Luo, Na, et al.
Publicado: (2018)